HercepTest is a semi-quantitative immunohistochemical assay for determination of HER2 protein (c-erbB-2 oncoprotein) overexpression in breast cancer tissues routinely processed for histological evaluation and formalin-fixed, paraffin-embedded cancer tissue from patients with adenocarcinoma of the stomach, including the gastroesophageal junction. HercepTest with the indication adenocarcinoma of the stomach, including the gastroesophageal junction, is not available on selected markets. HercepTest specifically demonstrates overexpression of HER2 protein. HercepTest is indicated as an aid in the assessment of patients for whom Herceptin™ (trastuzumab) treatment is being considered.
HercepTest™ and Herceptin™ are trademarks of Genentech, Inc. subject to licenses held by Dako Denmark A/S and F. Hoffmann-La Roche Ltd.